Cargando…

Pulmonary administration of remdesivir in the treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Rasmussen, Henrik Berg, Hansen, Peter Riis, Taboureau, Olivier, Thomsen, Ragnar, Jürgens, Gesche
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498113/ https://www.ncbi.nlm.nih.gov/pubmed/32944838 http://dx.doi.org/10.1208/s12248-020-00506-4

Ejemplares similares

Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2021)

Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2022)

Combined Ensemble Docking and Machine Learning in Identification of Therapeutic Agents with Potential Inhibitory Effect on Human CES1
por: Briand, Eliane, et al.
Publicado: (2019)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir for the treatment of COVID-19: author's response
por: Lee, Todd C., et al.
Publicado: (2023)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2022)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2023)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Does Remdesivir maintain the race in the general treatment protocol of COVID-19?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021)

Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021)

Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)
por: Pallotto, Carlo, et al.
Publicado: (2021)

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate
por: Kaddurah‐Daouk, Rima, et al.
Publicado: (2018)

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2023)

Indian perspective of remdesivir: A promising COVID-19 drug
por: Singh, Devendra, et al.
Publicado: (2020)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Anaphylaxis Due to Remdesivir
por: Hopkins, Brian J., et al.
Publicado: (2021)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

Successful management of remdesivir extravasation
por: Conde-Estévez, David, et al.
Publicado: (2022)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19
por: Kumar, Neeraj, et al.
Publicado: (2021)

Status of Remdesivir: Not Yet Beyond Question!
por: Chatterjee, Saptarshi
Publicado: (2021)

Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing
por: Trkulja, Vladimir
Publicado: (2021)

Prediction of remdesivir resistance in COVID-19 illness: Need for development of clinical laboratory test
por: Kumar, Deepak, et al.
Publicado: (2021)

Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis
por: Lucijanic, Marko, et al.
Publicado: (2022)

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
por: Sun, Duxin
Publicado: (2020)

Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
por: Yoon, Jin Gu, et al.
Publicado: (2022)

Response to: Status of Remdesivir: Not Yet Beyond Question!
por: Saha, Abinit, et al.
Publicado: (2021)

Bradycardia due to remdesivir: Report of two cases()
por: Cebrián Lara, Laura, et al.
Publicado: (2022)

Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease
por: Daunt, Anna, et al.
Publicado: (2020)

Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis
por: Tempestilli, Massimo, et al.
Publicado: (2021)

Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
por: Cillóniz, Catia, et al.
Publicado: (2023)

The impact of an antimicrobial stewardship program restriction on remdesivir prescribing
por: Zeitler, Kristen E., et al.
Publicado: (2022)

Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit
por: Sun, Duxin
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mbvhkm3tk1v3fq7074d65q0l7k